JP2019534867A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534867A5 JP2019534867A5 JP2019516407A JP2019516407A JP2019534867A5 JP 2019534867 A5 JP2019534867 A5 JP 2019534867A5 JP 2019516407 A JP2019516407 A JP 2019516407A JP 2019516407 A JP2019516407 A JP 2019516407A JP 2019534867 A5 JP2019534867 A5 JP 2019534867A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cannabidiol
- semi
- alkane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 8
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 6
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 4
- 229950011318 cannabidiol Drugs 0.000 claims 4
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 4
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 4
- 102000018208 Cannabinoid Receptor Human genes 0.000 claims 2
- 108050007331 Cannabinoid receptor Proteins 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16191194.6 | 2016-09-28 | ||
| EP16191194 | 2016-09-28 | ||
| EP17168172.9 | 2017-04-26 | ||
| EP17168172 | 2017-04-26 | ||
| PCT/EP2017/074545 WO2018060282A1 (en) | 2016-09-28 | 2017-09-27 | Compositions comprising a cannabinoid receptor binding ligand |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534867A JP2019534867A (ja) | 2019-12-05 |
| JP2019534867A5 true JP2019534867A5 (enExample) | 2020-04-09 |
Family
ID=59966776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516407A Pending JP2019534867A (ja) | 2016-09-28 | 2017-09-27 | カンナビノイド受容体結合リガンドを含む組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190343793A1 (enExample) |
| EP (2) | EP3698785A1 (enExample) |
| JP (1) | JP2019534867A (enExample) |
| KR (1) | KR20190060787A (enExample) |
| CN (1) | CN109803650A (enExample) |
| AU (1) | AU2017333420A1 (enExample) |
| BR (1) | BR112019006194A2 (enExample) |
| CA (1) | CA3036313A1 (enExample) |
| MX (1) | MX2019003544A (enExample) |
| WO (1) | WO2018060282A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2547323T3 (en) | 2010-03-17 | 2016-05-02 | Novaliq Gmbh | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INCREASED INTRAOCULAR PRESSURE |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| CN106511322B (zh) | 2012-09-12 | 2021-09-17 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| PL3181119T3 (pl) | 2012-09-12 | 2020-01-31 | Novaliq Gmbh | Kompozycje semifluorowanych alkanów do zastosowania w leczeniu suchego zapalenia spojówki i rogówki |
| AU2014295052B2 (en) | 2013-07-23 | 2018-08-30 | Novaliq Gmbh | Stabilized antibody compositions |
| CN110693825B (zh) | 2015-09-30 | 2022-03-08 | 诺瓦利克有限责任公司 | 用于眼部给药的半氟化化合物 |
| CN120754071A (zh) | 2015-09-30 | 2025-10-10 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| CN109475707A (zh) | 2016-05-03 | 2019-03-15 | 精呼吸股份有限公司 | 用于输送流体到肺部系统的液滴输送装置及其使用方法 |
| DK3442480T3 (da) | 2016-06-23 | 2020-01-13 | Novaliq Gmbh | Fremgangsmåde til topisk indgivelse |
| MX2019003363A (es) | 2016-09-22 | 2019-10-02 | Novaliq Gmbh | Composiciones farmaceuticas para usarse en la terapia de la blefaritis. |
| WO2018055101A1 (en) | 2016-09-23 | 2018-03-29 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| US10732712B2 (en) * | 2016-12-27 | 2020-08-04 | Facebook Technologies, Llc | Large scale integration of haptic devices |
| EP3612228B1 (en) | 2017-04-21 | 2023-08-23 | Dermaliq Therapeutics, Inc. | Iodine compositions |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| US11723861B2 (en) | 2017-09-27 | 2023-08-15 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| US11738158B2 (en) | 2017-10-04 | 2023-08-29 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device and methods of use |
| CA3082192A1 (en) | 2017-11-08 | 2019-05-16 | Pneuma Respiratory, Inc. | Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use |
| KR20200128407A (ko) | 2018-03-02 | 2020-11-12 | 노바리크 게엠베하 | 네비볼롤을 포함하는 약제학적 조성물 |
| CN112153970A (zh) | 2018-04-27 | 2020-12-29 | 诺瓦利克有限责任公司 | 用于治疗青光眼的包含他氟前列素的眼用组合物 |
| WO2020074697A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| EP3917923A4 (en) * | 2019-02-01 | 2023-02-08 | Aerie Pharmaceuticals, Inc. | Compounds, compositions and methods for treatment of myopia |
| CN113710228A (zh) | 2019-02-13 | 2021-11-26 | 诺瓦利克有限责任公司 | 用于治疗眼部新生血管形成的组合物和方法 |
| JP2022546980A (ja) | 2019-09-06 | 2022-11-10 | ノバリック ゲーエムベーハー | ブドウ膜炎の治療のための眼科用組成物 |
| CA3173494A1 (en) * | 2020-09-24 | 2022-03-31 | Michael Foster DAVIS | Cannabinoid composition comprising at least 50% carrier |
| WO2022074541A1 (en) * | 2020-10-05 | 2022-04-14 | Max Biology Co. Ltd. | Cannabinoid-containing compositions and use for treating and preventing diseases |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| AU2022217160A1 (en) | 2021-02-03 | 2023-08-17 | Ads Therapeutics Llc | Topical ophthalmological compositions |
| EP4659870A2 (en) | 2021-06-22 | 2025-12-10 | Pneuma Respiratory, Inc. | Droplet delivery device with push ejection |
| EP4415708A4 (en) * | 2021-10-13 | 2025-07-30 | Pneuma Respiratory Inc | COMPOSITIONS FOR THE ADMINISTRATION OF CANNABINOIDS |
| EP4558199A1 (en) | 2022-07-18 | 2025-05-28 | Pneuma Respiratory, Inc. | Small step size and high resolution aerosol generation system and method |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19536504C2 (de) * | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| CN101516333A (zh) | 2006-08-04 | 2009-08-26 | 英西斯治疗学股份有限公司 | 水性屈大麻酚制剂 |
| US8222292B2 (en) | 2007-08-06 | 2012-07-17 | Insys Therapeutics, Inc. | Liquid cannabinoid formulations |
| CA2741862C (en) | 2008-10-31 | 2017-10-17 | Mahmoud A. Elsohly | Compositions containing delta-9-thc-amino acid esters and process of preparation |
| AT509000B1 (de) * | 2009-10-23 | 2012-12-15 | Rausch Peter | Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen |
| EP2335735A1 (en) * | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| EP2444063A1 (en) * | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
| CN106511322B (zh) * | 2012-09-12 | 2021-09-17 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| PL3181119T3 (pl) * | 2012-09-12 | 2020-01-31 | Novaliq Gmbh | Kompozycje semifluorowanych alkanów do zastosowania w leczeniu suchego zapalenia spojówki i rogówki |
| AU2014332488B2 (en) | 2013-10-09 | 2017-03-09 | Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee | Methods and compositions for treating and preventing signs or symptoms of eye disease |
| WO2015074137A1 (en) | 2013-11-20 | 2015-05-28 | Mary Lynch | Compositions and methods for treatment of ocular inflammation and pain |
| MA41299A (fr) | 2014-12-30 | 2017-11-07 | Axim Biotechnologies Inc | Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite |
-
2017
- 2017-09-27 EP EP20159519.6A patent/EP3698785A1/en not_active Withdrawn
- 2017-09-27 MX MX2019003544A patent/MX2019003544A/es unknown
- 2017-09-27 CN CN201780058931.9A patent/CN109803650A/zh not_active Withdrawn
- 2017-09-27 JP JP2019516407A patent/JP2019534867A/ja active Pending
- 2017-09-27 AU AU2017333420A patent/AU2017333420A1/en not_active Abandoned
- 2017-09-27 BR BR112019006194A patent/BR112019006194A2/pt not_active IP Right Cessation
- 2017-09-27 US US16/337,617 patent/US20190343793A1/en not_active Abandoned
- 2017-09-27 WO PCT/EP2017/074545 patent/WO2018060282A1/en not_active Ceased
- 2017-09-27 CA CA3036313A patent/CA3036313A1/en not_active Withdrawn
- 2017-09-27 EP EP17772438.2A patent/EP3518921B1/en active Active
- 2017-09-27 KR KR1020197010976A patent/KR20190060787A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534867A5 (enExample) | ||
| Sambhara et al. | Glaucoma management: relative value and place in therapy of available drug treatments | |
| JP2018529693A5 (enExample) | ||
| JP7042274B2 (ja) | 眼内炎症性眼疾患の治療のためのタクロリムスを含む組成物 | |
| JP2015531344A5 (enExample) | ||
| JP2019532931A5 (enExample) | ||
| JP2018531233A5 (enExample) | ||
| JP6824270B2 (ja) | 生物活性親油性化合物を有するｐｅｇ化脂質ナノ粒子 | |
| IL273531B2 (en) | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases | |
| ES2540151B1 (es) | Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico | |
| EP3397255A1 (en) | Compositions for the treatment of presbyopia | |
| JP2009137971A (ja) | 薬剤および薬剤キット | |
| JP7787129B2 (ja) | 眼科組成物 | |
| ES2324130B1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes reductores de la hipertension ocular. | |
| US20230043428A1 (en) | Compositions and methods for use of cannabinoids for neuroprotection | |
| WO2019024433A1 (zh) | 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用 | |
| US9187468B2 (en) | Topical ocular analgesic agents | |
| WO2016182032A1 (ja) | アゾール系抗真菌薬の眼瞼皮膚への投与 | |
| JP2005047909A (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
| JP3142559B2 (ja) | 止痒剤としての血小板活性化因子拮抗剤の用途 | |
| JPWO2006098292A1 (ja) | 眼疾患治療剤 | |
| JP7417531B2 (ja) | 選択的ｓｙｋ阻害剤の使用方法および医薬組成物 | |
| CN121263183A (zh) | 吡美莫司用于治疗患者的特征在于牛津分级量表角膜染色评分为4或5分的干眼症的用途 | |
| KR20130108376A (ko) | 신경 보호 작용을 갖는 약제 배합 | |
| WO2023152644A1 (en) | Pharmaceutical composition of lifitegrast and loteprednol etabonate |